Relationship Between Masticatory Efficiency and Occlusal Parameters Established in T-Scan II System

The aim of this investigation was to establish possible correlation between parameters of occlusion and masticatory efficiency. MATERIAL: Data were obtained in 15 healthy persons, 23-31 years of age (mean 25 years) with correct own dentition and without any disturbances of the stomatognathic system. METHODS: Masticatory efficiency was measured using Optosil test modified by Slagter et al. after 20 and 80 cycles of chewing. It the time of chewing for 20 and 80 cycles of chewing was also established. Analysis of occlusion was made using T-scan II computerized system. Registration of occlusion was obtained before measuring masticatory efficiency after 20 and 80 cycles of chewing. Statistical analysis was made and p<0.05 was statistically significant. RESULTS: The time of chewing for 20 cycles and for 80 cycles respectively, mean 16 s +/- 3.0, and 55.6s +/- 9.5) reduction of particle size was about 1.5 mm. Time to maximal force ofpressure was shorter when chewing was longer. Maximal force of pressure for a unit of deflection indicator surface was higher after chewing. Share of sides of the teeth arch was about 59 per cent in all measurements. Maximal force of pressure for a unit of deflection indicator surface was correlated with the time of chewing for 20 cycles of chewing (p <0.05). Correlation of time from the first contact of teeth to maximal force of pressure and maximal force of pressure for a unit of deflection indicator surface was statistically significant for 80 cycles . There was no evident correlation between values of X50 and occlusal parameters established in computerizedanalysis. CONCLUSION: Chewing ability is correla ted with occlusion although this relationship is not significant

Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study

Background: Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterised by progressive neurological degeneration, where the rate of neurological disease progression varies depending on age at neurological onset. We report longitudinal data on functional disease progression and safety observations in patients in the international NPC Registry who received continuous treatment with miglustat. Methods: The NPC Registry is a prospective observational cohort of NP-C patients. Enrolled patients who received ≥1 year of continuous miglustat therapy (for ≥90 % of the observation period, with no single treatment interruption >28 days) were included in this analysis. Disability was measured using a scale rating the four domains, ambulation, manipulation, language and swallowing from 0 (normal) to 1 (worst). Neurological disease progression was analysed in all patients based on: 1) annual progression rates between enrolment and last follow up, and; 2) categorical analysis with patients categorised as 'improved/stable' if ≥3/4 domain scores were lower/unchanged, and as 'progressed' if <3 scores were lower/unchanged between enrolment and last follow-up visit. Results: In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy. The mean (SD) miglustat exposure during the observation period (enrolment to last follow-up) was 2.0 (0.7) years. Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations. The mean (95%CI) composite disability score among all patients was 0.37 (0.32,0.42) at enrolment and 0.44 (0.38,0.50) at last follow-up visit, and the mean annual progression rate was 0.038 (0.018,0.059). Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset. Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset. Safety findings were consistent with previous data. Conclusions: Disability status was improved/stable in the majority of patients who received continuous miglustat therapy for an average period of 2 years

Kamituga: Digital Gold

Questa è una sala espositiva all'interno della più ampia mostra "Planet Digital" (https://www.planetdigital.ch/en) ospitata dal Museum für Gestaltung, Zurigo, Svizzera (dal 20.2.2022 al 6.6.2022